MAPT and Alzheimer disease: Finally, we corroborate previous studies which showed that p-tau205 positivity is an important milestone in AD progression as a biomarker of tau pathology [3, 17, 24], but most importantly, our results suggest that the underlying extend of tau deposition might be staged by further stratifying p-tau205 positive cases using NTA-tau, a biomarker of mid-to-late tau pathology in AD [18, 19].